ArticleRadiology. Imaging cancer2025
Deep Learning Classification of Prostate Cancer Using MRI Histopathologic Data.
Article in Radiology. Imaging cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prioritising Data Quality Governance for AI in Prostate Cancer: A Methodological Proof-of-Concept Study Using Neural Networks for Risk Stratification.Diagnostics (Basel, Switzerland) · 2026Article
- An MRI Histopathology-based Deep Learning Approach for the Classification of Prostate Cancer.Radiology. Imaging cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To evaluate the diagnostic capability of MR histopathology (MRH) for identifying prostate cancer and guiding selection of imaging parameters for clinical MRH acquisition. Materials and Methods This retrospective study was conducted on a dataset of histologic slides of radical prostatectomy specimens with prostate cancer collected between 2009 and 2011. The dataset was used to perform an in silico validation of MRH, a method of assessing tissue texture that trades spatial coherence for spatial resolution surpassing traditional MRH by over an order of magnitude. The MRH measurement process was computationally recreated on the annotated slides, creating a dataset of spectral intensities at submillimeter wavelengths. Novel artificial intelligence analytics methods were developed to classify spectral data as normal or containing prostate cancer, and diagnostically informative parameters were determined. Results A set of spatial frequencies that maximized discriminative ability between healthy and cancerous tissue (area under the receiver operating characteristic curve, 0.79) was identified, thereby informing future clinical implementation. Integrating spatial context into the model denoised the inferential results and improved classification performance (area under the receiver operating characteristic curve, 0.84) and moreover enabled the estimation of lesion size. Conclusion This study demonstrates the feasibility of MRH as a novel method for prostate cancer detection and identifies imaging parameters that may guide clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.